Predictors of clinical response to systemic steroids in active ulcerative colitis

被引:28
作者
Bernal, Isabel [1 ]
Manosa, Miriam [1 ]
Domenech, Eugeni [1 ]
Garcia-Planella, Esther [1 ]
Navarro, Merce [1 ]
Lorenzo-Zuniga, Vicente [1 ]
Cabre, Eduard [1 ]
Gassull, Miquel Angel [1 ]
机构
[1] Hosp Badalona Germans Trias & Pujol, Dept Gastroenterol, Badalona 08916, Spain
关键词
ulcerative colitis; inflammatory bowel disease; steroids; refractoriness;
D O I
10.1007/s10620-006-9103-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Although systemic steroids remain as the gold standard for the treatment of acute moderate to severe active ulcerative colitis (UC), 15-57% of patients do not achieve clinical remission. We sought to identify clinical, biological, or radiologic predictive factors of response to steroid treatment in acute UC attacks. The medical records of 39 consecutive patients admitted for an acute attack of UC and treated with systemic steroids, were reviewed. Epidemiologic, demographic, and clinical data at baseline and clinical data 3 days after starting steroid treatment were registered. Treatment failure was defined as the need of IV cyclosporine or colectomy before hospital discharge. Twenty-four patients (62%) responded to systemic steroids. Thirteen out of the 15 nonresponders, were treated with IV cyclosporine, avoiding colectomy in 7 cases (54%). More than six bowel movements per day at the third day of treatment, blood in stools in the third day of therapy, extensive UC, and the presence of malnutrition were associated with steroid treatment failure, but only blood in stools (P=.04), and more than six movements per day (P=.012) after 3 days of treatment, were found to be independent predictive factors of steroid refractoriness. In conclusion, clinical evaluation 3 days after starting systemic steroids seems to be the best tool to assess short-term prognosis.
引用
收藏
页码:1434 / 1438
页数:5
相关论文
共 20 条
  • [1] Prognosis of severe attacks in ulcerative colitis:: effect of intensive medical treatment
    Benazzato, L
    D'Incà, R
    Grigoletto, F
    Perissinotto, E
    Medici, V
    Angriman, I
    Sturniolo, GC
    [J]. DIGESTIVE AND LIVER DISEASE, 2004, 36 (07) : 461 - 466
  • [2] Carbonnel F, 2000, ALIMENT PHARM THERAP, V14, P273
  • [3] CHAKRAVARTY BJ, 1993, AM J GASTROENTEROL, V88, P852
  • [4] SMALL-BOWEL GAS IN SEVERE ULCERATIVE-COLITIS
    CHEW, CN
    NOLAN, DJ
    JEWELL, DP
    [J]. GUT, 1991, 32 (12) : 1535 - 1537
  • [5] Cottone M, 2001, AM J GASTROENTEROL, V96, P773, DOI 10.1111/j.1572-0241.2001.03620.x
  • [6] Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis
    Domènech, E
    Garcia-Planella, E
    Bernal, I
    Rosinach, M
    Cabré, E
    Fluvià, L
    Boix, J
    Gassull, MA
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (12) : 2061 - 2065
  • [7] The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
    Faubion, WA
    Loftus, EV
    Harmsen, WS
    Zinsmeister, AR
    Sandborn, WJ
    [J]. GASTROENTEROLOGY, 2001, 121 (02) : 255 - 260
  • [8] Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease
    Forcione, DG
    Rosen, MJ
    Kisiel, JB
    Sands, BE
    [J]. GUT, 2004, 53 (08) : 1117 - 1122
  • [9] Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery
    Ho, GT
    Mowat, C
    Goddard, CJR
    Fennell, JM
    Shah, NB
    Prescott, RJ
    Satsangi, J
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (10) : 1079 - 1087
  • [10] JARNEROT G, 1985, GASTROENTEROLOGY, V89, P1005